Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Metabolic Changes in HIV Patients on ART
NCT07336797Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in obesity, metabolic syndrome. Started Sep 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT07336797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336797.